The European autonomous therapeutic cannabis organisation is set to enter the German market. EMMAC Life Sciences Ltd has incorporated About Nature Health GmbH (About Nature), a subsidiary of the company. EMMAC hopes that this will lead to the marketing and licensing of their products in Germany.
About Nature has entered into a supply agreement with CC Pharma (a leading imported of EU-sourced pharmaceuticals in the German market. This follows a partnership between About Nature and EMMAC’s Spanish GMP certified laboratory and development facilities.
The agreement allows EMMAC to import cannabis products, and raw material into the largest medical cannabis market in the world.
It is estimated that 7.5% of medications used to treat sleep, anxiety and pain prescriptions in Germany will eventually be replaced with medical cannabis. This could lead to the medical cannabis market in Germany producing more than $5 billion in revenue for global cannabis producers.
Antonio Costanzo, CEO of EMMAC, said:
“The choice by CC Pharma to appropriate EMMAC medicinal cannabis item in Germany approves our pledge to conveying the most elevated quality item and we are charmed to declare the Agreement today. Germany is a significant market for EMMAC and we are focused on developing our local nearness, driven by general supervisor, Florian Witt, to guarantee that we gain by the huge business opportunity.
EMMAC has had a positive start to 2019 and our entry into the German market is the latest significant milestone for the Group. Our tie-up with CC Pharma is a clear demonstration of the significant progress being made at EMMAC and is complementary to the acquisitions completed and key milestones achieved in 2019 in the UK, Malta, Spain and Switzerland. I look forward to updating our stakeholders as we continue to execute on our vision to become the leading European medical cannabis company.”